BillionToOne Reports Strong Q4 and 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy BLLN?
Source: seekingalpha
- Significant Revenue Growth: BillionToOne reported total revenue of $305.1 million in 2025, a 100% increase from $152.6 million in 2024, driven by a 51% rise in total tests delivered and a 35% increase in overall average selling price, indicating strong market demand.
- Improved Gross Margin: The gross profit for 2025 was $208.5 million, with a gross margin of 68%, up from 53% in 2024, primarily due to higher overall selling prices and reduced cost-per-test, showcasing effective cost control and pricing strategies.
- Positive Operating Income: Operating income for 2025 was $16 million, a significant turnaround from a loss of $47.1 million in 2024, with an operating margin of 5%, reflecting successful management of operating expenses and enhancing confidence in future profitability.
- Strong Cash Position: As of December 31, 2025, BillionToOne held approximately $496 million in cash and cash equivalents, providing robust financial support for future expansion and investments, with projected total revenue for 2026 expected to reach between $430 million and $445 million, representing a growth of 41% to 46%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLLN
Wall Street analysts forecast BLLN stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 83.140
Low
110.00
Averages
137.83
High
160.00
Current: 83.140
Low
110.00
Averages
137.83
High
160.00
No data
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BillionToOne Reports Strong Q4 and 2025 Financial Results
- Significant Revenue Growth: BillionToOne reported total revenue of $305.1 million in 2025, a 100% increase from $152.6 million in 2024, driven by a 51% rise in total tests delivered and a 35% increase in overall average selling price, indicating strong market demand.
- Improved Gross Margin: The gross profit for 2025 was $208.5 million, with a gross margin of 68%, up from 53% in 2024, primarily due to higher overall selling prices and reduced cost-per-test, showcasing effective cost control and pricing strategies.
- Positive Operating Income: Operating income for 2025 was $16 million, a significant turnaround from a loss of $47.1 million in 2024, with an operating margin of 5%, reflecting successful management of operating expenses and enhancing confidence in future profitability.
- Strong Cash Position: As of December 31, 2025, BillionToOne held approximately $496 million in cash and cash equivalents, providing robust financial support for future expansion and investments, with projected total revenue for 2026 expected to reach between $430 million and $445 million, representing a growth of 41% to 46%.
See More
Napean Trading Acquires Stake in BillionToOne
- New Investment Insight: On February 13, 2026, Singapore-based Napean Trading & Investment disclosed a new position in BillionToOne, acquiring 233,333 shares valued at $19,095,973, indicating strong confidence in the company's prospects.
- Asset Allocation Impact: This acquisition represents 3.71% of Napean's reportable U.S. equity assets under management, positioning BillionToOne alongside larger investments in Robinhood and Navan, highlighting its strategic importance.
- Market Performance Analysis: As of February 13, 2026, BillionToOne shares were priced at $88.61, reflecting a 48% increase from the $60 IPO price, which underscores market recognition of its growth potential, especially with a projected revenue growth of 40% to 45% for 2026.
- Profitability Outlook: BillionToOne anticipates achieving positive GAAP operating income in both 2025 and 2026, and if its high-sensitivity prenatal and oncology tests gain clinical traction, the company's valuation could expand, attracting long-term investor interest.
See More
BillionToOne Launches New Liquid Biopsy Applications for Enhanced Cancer Treatment Insights
- New Application Launch: BillionToOne introduces Northstar PGx and Northstar Select CH, expanding the clinical insights of the Northstar Select platform, capable of uncovering over 50% more clinically actionable alterations from the same blood sample, significantly enhancing the accuracy of cancer treatment decisions.
- Pharmacogenomics Integration: Northstar PGx provides pharmacogenomic insights into the DPYD and UGT1A1 genes, assisting physicians in optimizing dosing and monitoring for 5-FU and irinotecan therapies without extending turnaround time, thereby reducing chemotherapy toxicity risks.
- Clonal Hematopoiesis Testing: Northstar Select CH employs targeted genomic DNA sequencing of white blood cells to accurately distinguish tumor-derived alterations from non-tumor findings, achieving over 99% accuracy, thus avoiding unnecessary treatments and toxicity.
- Clinical Decision Support: The launch of these two new applications further strengthens the Northstar platform's competitiveness in the liquid biopsy field, enabling clinicians to obtain deeper clinically relevant insights from a single blood draw, optimizing patient treatment plans.
See More
BillionToOne Expands Leadership in HDFN and FNAIT Testing
- Innovative Test Launch: BillionToOne has launched the expanded UNITY Red Blood Cell Fetal Antigen NIPT and the first-ever Platelet Fetal Antigen NIPT, marking the first non-invasive prenatal tests in the U.S. that cover approximately 99% of antigens associated with HDFN, significantly enhancing detection capabilities for both HDFN and FNAIT.
- Clinical Efficacy Improvement: The UNITY Fetal Antigen NIPT has demonstrated over 99.9% sensitivity and specificity with 100% concordance with neonatal outcomes in clinical studies, enabling early and accurate determination of fetal antigen status, thereby reducing unnecessary monitoring and interventions and optimizing clinical decision-making.
- Guideline Update Impact: The clinical validity of this test has contributed to recent updates in expert practice guidelines published in JAMA Network, recommending the use of cfDNA testing to determine fetal antigen status, thereby reshaping the standard of care for HDFN and improving patient care quality.
- Market Demand Fulfillment: The Platelet Fetal Antigen NIPT addresses a significant clinical gap for pregnancies affected by platelet antigen incompatibility, allowing for non-invasive determination of fetal antigen incompatibility and enabling proactive risk stratification in the management of FNAIT, thus enhancing care for high-risk pregnancies.
See More
BillionToOne Expands Leadership in HDFN and Launches FNAIT Testing
- Innovative Test Launch: BillionToOne has launched the expanded UNITY Red Blood Cell Fetal Antigen NIPT and the first-ever Platelet Fetal Antigen NIPT, marking the first non-invasive prenatal tests in the U.S. that cover approximately 99% of antigens associated with HDFN, significantly enhancing detection capabilities for both HDFN and FNAIT.
- Enhanced Clinical Validity: The UNITY Fetal Antigen NIPT demonstrates over 99.9% sensitivity and specificity, achieving 100% concordance with neonatal outcomes, which allows for early and accurate determination of fetal antigen status, thereby reducing unnecessary monitoring and interventions and optimizing clinical decision-making.
- Guideline Update Impact: The clinical validity of UNITY Fetal Antigen NIPT has contributed to recent updates in expert practice guidelines published in JAMA Network, recommending cfDNA testing for fetal antigen status, which reshapes the standard of care for HDFN and enhances patient treatment experiences.
- Market Demand Fulfillment: The Platelet Fetal Antigen NIPT launched by BillionToOne addresses significant clinical gaps for pregnancies affected by platelet antigen incompatibility, enabling non-invasive determination of fetal antigen incompatibility and bringing innovation to the management of FNAIT, thus improving risk stratification for high-risk pregnancies.
See More
2025 IPO Class: 3 Stocks Showing Positive Chart Trends
- Initial Public Offerings (IPOs): IPOs provide investors with new insights into the market landscape.
- Investment Opportunities: They can also reveal previously overlooked investment opportunities.
See More
BillionToOne Reports Strong Q4 and 2025 Financial Results
- Significant Revenue Growth: BillionToOne reported total revenue of $305.1 million in 2025, a 100% increase from $152.6 million in 2024, driven by a 51% rise in total tests delivered and a 35% increase in overall average selling price, indicating strong market demand.
- Improved Gross Margin: The gross profit for 2025 was $208.5 million, with a gross margin of 68%, up from 53% in 2024, primarily due to higher overall selling prices and reduced cost-per-test, showcasing effective cost control and pricing strategies.
- Positive Operating Income: Operating income for 2025 was $16 million, a significant turnaround from a loss of $47.1 million in 2024, with an operating margin of 5%, reflecting successful management of operating expenses and enhancing confidence in future profitability.
- Strong Cash Position: As of December 31, 2025, BillionToOne held approximately $496 million in cash and cash equivalents, providing robust financial support for future expansion and investments, with projected total revenue for 2026 expected to reach between $430 million and $445 million, representing a growth of 41% to 46%.
See More
Napean Trading Acquires Stake in BillionToOne
- New Investment Insight: On February 13, 2026, Singapore-based Napean Trading & Investment disclosed a new position in BillionToOne, acquiring 233,333 shares valued at $19,095,973, indicating strong confidence in the company's prospects.
- Asset Allocation Impact: This acquisition represents 3.71% of Napean's reportable U.S. equity assets under management, positioning BillionToOne alongside larger investments in Robinhood and Navan, highlighting its strategic importance.
- Market Performance Analysis: As of February 13, 2026, BillionToOne shares were priced at $88.61, reflecting a 48% increase from the $60 IPO price, which underscores market recognition of its growth potential, especially with a projected revenue growth of 40% to 45% for 2026.
- Profitability Outlook: BillionToOne anticipates achieving positive GAAP operating income in both 2025 and 2026, and if its high-sensitivity prenatal and oncology tests gain clinical traction, the company's valuation could expand, attracting long-term investor interest.
See More
BillionToOne Launches New Liquid Biopsy Applications for Enhanced Cancer Treatment Insights
- New Application Launch: BillionToOne introduces Northstar PGx and Northstar Select CH, expanding the clinical insights of the Northstar Select platform, capable of uncovering over 50% more clinically actionable alterations from the same blood sample, significantly enhancing the accuracy of cancer treatment decisions.
- Pharmacogenomics Integration: Northstar PGx provides pharmacogenomic insights into the DPYD and UGT1A1 genes, assisting physicians in optimizing dosing and monitoring for 5-FU and irinotecan therapies without extending turnaround time, thereby reducing chemotherapy toxicity risks.
- Clonal Hematopoiesis Testing: Northstar Select CH employs targeted genomic DNA sequencing of white blood cells to accurately distinguish tumor-derived alterations from non-tumor findings, achieving over 99% accuracy, thus avoiding unnecessary treatments and toxicity.
- Clinical Decision Support: The launch of these two new applications further strengthens the Northstar platform's competitiveness in the liquid biopsy field, enabling clinicians to obtain deeper clinically relevant insights from a single blood draw, optimizing patient treatment plans.
See More
BillionToOne Expands Leadership in HDFN and FNAIT Testing
- Innovative Test Launch: BillionToOne has launched the expanded UNITY Red Blood Cell Fetal Antigen NIPT and the first-ever Platelet Fetal Antigen NIPT, marking the first non-invasive prenatal tests in the U.S. that cover approximately 99% of antigens associated with HDFN, significantly enhancing detection capabilities for both HDFN and FNAIT.
- Clinical Efficacy Improvement: The UNITY Fetal Antigen NIPT has demonstrated over 99.9% sensitivity and specificity with 100% concordance with neonatal outcomes in clinical studies, enabling early and accurate determination of fetal antigen status, thereby reducing unnecessary monitoring and interventions and optimizing clinical decision-making.
- Guideline Update Impact: The clinical validity of this test has contributed to recent updates in expert practice guidelines published in JAMA Network, recommending the use of cfDNA testing to determine fetal antigen status, thereby reshaping the standard of care for HDFN and improving patient care quality.
- Market Demand Fulfillment: The Platelet Fetal Antigen NIPT addresses a significant clinical gap for pregnancies affected by platelet antigen incompatibility, allowing for non-invasive determination of fetal antigen incompatibility and enabling proactive risk stratification in the management of FNAIT, thus enhancing care for high-risk pregnancies.
See More
BillionToOne Expands Leadership in HDFN and Launches FNAIT Testing
- Innovative Test Launch: BillionToOne has launched the expanded UNITY Red Blood Cell Fetal Antigen NIPT and the first-ever Platelet Fetal Antigen NIPT, marking the first non-invasive prenatal tests in the U.S. that cover approximately 99% of antigens associated with HDFN, significantly enhancing detection capabilities for both HDFN and FNAIT.
- Enhanced Clinical Validity: The UNITY Fetal Antigen NIPT demonstrates over 99.9% sensitivity and specificity, achieving 100% concordance with neonatal outcomes, which allows for early and accurate determination of fetal antigen status, thereby reducing unnecessary monitoring and interventions and optimizing clinical decision-making.
- Guideline Update Impact: The clinical validity of UNITY Fetal Antigen NIPT has contributed to recent updates in expert practice guidelines published in JAMA Network, recommending cfDNA testing for fetal antigen status, which reshapes the standard of care for HDFN and enhances patient treatment experiences.
- Market Demand Fulfillment: The Platelet Fetal Antigen NIPT launched by BillionToOne addresses significant clinical gaps for pregnancies affected by platelet antigen incompatibility, enabling non-invasive determination of fetal antigen incompatibility and bringing innovation to the management of FNAIT, thus improving risk stratification for high-risk pregnancies.
See More
2025 IPO Class: 3 Stocks Showing Positive Chart Trends
- Initial Public Offerings (IPOs): IPOs provide investors with new insights into the market landscape.
- Investment Opportunities: They can also reveal previously overlooked investment opportunities.
See More
